scholarly journals Role of androgen receptor expression in early stage ER+/PgR−/HER2– breast cancer

2020 ◽  
Vol 12 ◽  
pp. 175883592095835 ◽  
Author(s):  
Barbara Tagliaferri ◽  
Erica Quaquarini ◽  
Raffaella Palumbo ◽  
Emanuela Balletti ◽  
Daniele Presti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Early Stage ◽  
Tumor Biology ◽  
Growth Factor Receptor ◽  
Primary Objective ◽  
Receptor Expression ◽  
Prognostic Role ◽  
Her2 Breast Cancer

Background: Progesterone receptor (PgR) negative breast cancer (BC) is an aggressive subtype with poor prognosis and reduced response to endocrine treatments. Several studies have suggested that androgen receptor (AR) expression is associated with a favorable tumor biology, longer recurrence free survival (RFS), and overall survival. In the literature no data exist regarding the role of AR expression in early stage estrogen receptor (ER)+/PgR– BCs. The aim of this study was to evaluate the prognostic role of AR expression in this setting. Patients and methods: This is a monocentric retrospective study in which 208 patients who underwent surgical intervention for ER+/PgR−/Human Epidermal growth factor Receptor 2 (HER2)– BC were included. The primary objective was to analyze the relationship between AR expression and RFS. Results: At a median follow-up of 77 months, 75 patients (36%) had a disease relapse (all sites included). AR expression was significantly higher in patients who did not relapse compared with those who relapsed with an impact on RFS (hazard ratio [HR] = 0.99, p = 0.025). Patients with AR expression ⩾80% had a lower risk of relapse compared with those with AR <80% (HR = 0.53, p = 0.008). In addition, breast tumors with higher AR expression had good biological features (low ki67 and nuclear grade) compared with BCs with lower AR expression, at least partly explaining the different outcome. Conclusions: The results of this study support the potential prognostic role of AR in patients with ER+/PgR− BCs and may contribute to the identification of subgroups of high-risk patients.

scholarly journals Prognostic Role of Androgen Receptor Expression in Surgically Resected Early Breast Cancer Patients

2020 ◽  
Vol 23 (2) ◽  
pp. 182 ◽  
Author(s):  
Yaewon Yang ◽  
Ahrum Min ◽  
Kyung-Hun Lee ◽  
Han Suk Ryu ◽  
Tae-Yong Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Receptor Expression ◽  
Androgen Receptor Expression ◽  
Breast Cancer Patients ◽  
Prognostic Role

Prognostic role of androgen receptor expression in triple-negative breast cancer.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 1076-1076 ◽  
Author(s):  
Yanru Wang ◽  
Fang Yang ◽  
Yucai Wang ◽  
Fengming Zhong ◽  
Xiaoxiang Guan
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Receptor Expression ◽  
Androgen Receptor Expression ◽  
Prognostic Role

scholarly journals The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data

2016 ◽  
Vol 23 (11) ◽  
pp. 2702-2712 ◽  
Author(s):  
Ivana Bozovic-Spasojevic ◽  
Dimitrios Zardavas ◽  
Sylvain Brohée ◽  
Lieveke Ameye ◽  
Debora Fumagalli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Androgen Receptor ◽  
Gene Expression Data ◽  
Early Stage ◽  
Meta Analysis ◽  
Early Stage Breast Cancer ◽  
Expression Data ◽  
Prognostic Role

scholarly journals Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events

BMC Cancer ◽  
2012 ◽  
Vol 12 (1) ◽  
Author(s):  
Kate M Peters ◽  
Stacey L Edwards ◽  
Shalima S Nair ◽  
Juliet D French ◽  
Peter J Bailey ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Cancer Survival ◽  
Breast Cancer Survival ◽  
Receptor Expression ◽  
Androgen Receptor Expression ◽  
Epigenetic Events

scholarly journals Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer

Cancers ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 737 ◽  
Author(s):  
Denis M. Collins ◽  
Neil T. Conlon ◽  
Srinivasaraghavan Kannan ◽  
Chandra S. Verma ◽  
Lisa D. Eli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Adjuvant Treatment ◽  
Early Stage ◽  
Growth Factor Receptor ◽  
Her2 Positive ◽  
Her2 Breast Cancer ◽  
Epidermal Growth

An estimated 15–20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2/ERBB2/neu). Two small-molecule tyrosine kinase inhibitors (TKIs), lapatinib and neratinib, have been approved for the treatment of HER2-positive (HER2+) breast cancer. Lapatinib, a reversible epidermal growth factor receptor (EGFR/ERBB1/HER1) and HER2 TKI, is used for the treatment of advanced HER2+ breast cancer in combination with capecitabine, in combination with trastuzumab in patients with hormone receptor-negative metastatic breast cancer, and in combination with an aromatase inhibitor for the first-line treatment of HER2+ breast cancer. Neratinib, a next-generation, irreversible pan-HER TKI, is used in the US for extended adjuvant treatment of adult patients with early-stage HER2+ breast cancer following 1 year of trastuzumab. In Europe, neratinib is used in the extended adjuvant treatment of adult patients with early-stage hormone receptor-positive HER2+ breast cancer who are less than 1 year from the completion of prior adjuvant trastuzumab-based therapy. Preclinical studies have shown that these agents have distinct properties that may impact their clinical activity. This review describes the preclinical characterization of lapatinib and neratinib, with a focus on the differences between these two agents that may have implications for patient management.

Sign in / Sign up

Export Citation Format

Share Document